Could a “Gene Expression Atlas” Unlock the Secrets of Amyotrophic Lateral Sclerosis?

According to a story from MD Magazine, the team at Spatial Transcriptomics has utilized an innovative computational approach in order to map gene expression on the spinal cords of patients…

Continue Reading Could a “Gene Expression Atlas” Unlock the Secrets of Amyotrophic Lateral Sclerosis?

Enrollment Completed in Achromatopsia and Retinitis Pigmentosa Clinical Trials

ACHM and XLRP Achromatopsia (ACHM) is a rare, inherited retinal disease which causes impaired cone photoreceptor function. Patients experience light sensitivity so extreme that it can cause blindness during the…

Continue Reading Enrollment Completed in Achromatopsia and Retinitis Pigmentosa Clinical Trials
Pulmonary Hypertension Drugs are Effective for Some Sarcoidosis Patients, Study Says
oracast / Pixabay

Pulmonary Hypertension Drugs are Effective for Some Sarcoidosis Patients, Study Says

According to a story from Pulmonary Hypertension News, many patients with the rare disease sarcoidosis frequently experience lung complications. Included in these complications is pulmonary hypertension, a condition of elevated…

Continue Reading Pulmonary Hypertension Drugs are Effective for Some Sarcoidosis Patients, Study Says

Exciting Gene Therapy Progress in Huntington’s Disease and Spinocerebellar Ataxia

Huntington's Disease & SCAs  Huntington's disease (HD) and spinocerebellar ataxia (SCA) are both neurodegenerative diseases caused by the same type of error in the body's DNA. Essentially, the CAG or…

Continue Reading Exciting Gene Therapy Progress in Huntington’s Disease and Spinocerebellar Ataxia

Company Announces Plans to File for Conditional Marketing for Duchenne Muscular Dystrophy Drug in the EU

According to a story from Market Screener, the specialty pharmaceutical company Santhera Pharmaceuticals recently released an announcement in which the company revealed its intent to file for Conditional Marketing Authorization…

Continue Reading Company Announces Plans to File for Conditional Marketing for Duchenne Muscular Dystrophy Drug in the EU

uniQure Receives FDA Fast Track Designation for AMT 130 Gene Therapy for the Treatment of Huntingtons Disease

LEXINGTON, Mass. and AMSTERDAM, the Netherlands - uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,  announced that the U.S. Food and Drug…

Continue Reading uniQure Receives FDA Fast Track Designation for AMT 130 Gene Therapy for the Treatment of Huntingtons Disease

New Phase 1 Clinical Trial for Mastocytosis, MDS, and AML has Just Begun!

GT Biopharma has just announced that their Phase 1 clinical trial for Mastocytosis, Myelodysplastic Syndrome (MDS), and Acute Myeloid Leukemia (AML) has been authorized to begin. Although this investigation had previously…

Continue Reading New Phase 1 Clinical Trial for Mastocytosis, MDS, and AML has Just Begun!